Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.

The U.S. Food and Drug Administration is now requiring two common COVID-19 vaccines to update their warning labels to include ...

FRIDAY, June 27, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has added new warnings to the Pfizer and ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines ...

Solid phase III efficacy results for Moderna Inc.’s seasonal influenza vaccine, mRNA-1010, may lead the company to resubmit a ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...